Pharmaceuticals

BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand

BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...

2024-03-20 12:39 1646

Docquity enables Italian biopharmaceutical company Menarini to double HCP reach and engagement in Malaysia

* A Docquity client since 2021, Menarini Malaysia further engaged the platform to raise awareness among target HCPs on multimodal approaches to post-surgery pain management and recovery * Docquity's Awareness to Advocacy (A2A) Program, backed by its in-depth HCP network insights, droveMenarini...

2024-03-20 10:00 1404

Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences ...

2024-03-20 09:16 1343

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 08:30 1435

China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement

HANGZHOU, China, March 19, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...

2024-03-20 04:05 1618

SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology ...

2024-03-19 22:00 1114

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

ST. GALLEN, SWITZERLAND, March 19, 2024 /PRNewswire/ -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations ...

2024-03-19 19:09 1941

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo

Cognizant's AI and industry expertise, combined with the NVIDIA BioNeMo generative AI platform, create a strong foundation to improve outcomes in the healthcare and life sciences sectors TEANECK, N.J., March 19, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) is advancing the application of genera...

2024-03-19 12:01 2055

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...

2024-03-19 10:24 1025

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2024-03-19 08:00 1499

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...

2024-03-18 20:32 1875

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...

2024-03-18 19:25 1089

KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1

-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule ...

2024-03-18 18:02 1078

Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule

EAST RUTHERFORD, N.J., March 18, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it is nearing the completion of a 5-year,$100-million-dollar investment strategy, one year ahead of schedule. The project, which adds mo...

2024-03-18 18:00 1429

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened i...

2024-03-18 09:00 1541

/C O R R E C T I O N -- Sisram Medical Ltd/

In the news release, Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21, issued on 14-Mar-2024 by Sisram Medical Ltd over PR Newswire, we are advised by the company that regarding the time, specifically, the Israel Time, should read "2:00 p.m." ra...

2024-03-15 16:42 2600

Novartis expands its biopharmaceutical manufacturing site in Singapore

* Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market  * Set to generate 100 high skilled employment opportunities in Singapore's life science industry  SINGAPORE, March 15, 2024 /PRNewswire/ -- Novartis today...

2024-03-15 14:55 3196

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain, Qilu Pharmaceutical unveiled the Phase II clinical trial results for iparomlimab and tuvonralimab (QL1706) in an oral presentation....

2024-03-15 14:07 2129

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous ...

2024-03-15 13:56 1312

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

* 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases * Awardees representing 12 countries in Europe, the Americas, Asia and Africa , will receive research grants of up toUSD 600,000 per project * As part of the Seegene's...

2024-03-15 13:41 2061
123456 ... 291

Week's Top Stories